Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis

International Journal of Mycobacteriology

Volumn 1, Issue 4, 2012, Pages 177-179

  Ängeby, Kristian ^a   Juréen, Pontus ^b   Chryssanthou, Erja ^a   Schön, Thomas ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Antimycobacterial agents; Drug resistance; Drug susceptibility testing; Mycobacteria; Phenothiazines; Wild type MIC distributions

Indexed keywords

THIORIDAZINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; WILD TYPE;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 84887213417     PISSN: 22125531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2012.09.002     Document Type: Article

References (13)

1. Amaral L., Viveiros M., Molnar J., Kristiansen J.E. Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses" Recent Pat. Antiinfect. Drug Discov. 2011, F:84-87.
2. van Ingen J., van der Laan T., Amaral L., Dekhuijzen R., Boeree M.J., van Soolingen D. In vitro activity of thioridazine against mycobacteria. Int. J. Antimicrob. Agents 2009, 34:190-191.
3. van Soolingen D., Hernandez-Pando R., Orozco H., Aguilar D., Magis-Escurra C., Amaral L., et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010, 5:e12640.
4. Sohaskey C. Latent tuberculosis: is there a role for thioridazine?. Recent Pat. Antiinfect. Drug Discov. 2011, 6:139-146.
5. Rodrigues L., Machado D., Couto I., Amaral L., Viveiros M. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 2012, 12:695-700.
6. Ängeby K., Giske C.G., Juréen P., Schön T., Pasipanodya J.G., Gumbo T. Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2011, 55:4492-4493.
7. Schön T., Juréen P., Giske C.G., et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 2009, 64:786-793.
8. Ängeby K., Juréen P., Giske C.G., Chryssanthou E., Sturegård E., Nordvall M., et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 2010, 65:946-952.
9. Juréen P., Ängeby K., Sturegård E., Chryssanthou E., Giske C.G., Werngren J., et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J. Clin. Microbiol. 2010, 48:1853-1858.
10. Schön T., Juréen P., Chryssanthou E., Giske C.G., Sturegård E., Kahlmeter G., et al. Int. J. Tuberc. Lung Dis. 2011, 15:502-509.
11. Werngren J., Sturegård E., Juréen P., Ängeby K., Hoffner S.E., Schön T. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob. Agents Chemother. 2012, 56:1253-1257.
12. Ängeby K., Juréen P., Kahlmeter G., Hoffner S.E., Schön T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. WHO. 2012, 90:693-698.
13. Amaral L., Kristiansen J.E., Abebe L.S., Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 1996, 38:1049-1053.